<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004423</url>
  </required_header>
  <id_info>
    <org_study_id>199/13352</org_study_id>
    <secondary_id>UVTCM-FDR001021</secondary_id>
    <nct_id>NCT00004423</nct_id>
  </id_info>
  <brief_title>Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Assess the efficacy and safety of 4-aminosalicylic acid in patients with active Crohn's&#xD;
      disease of the small bowel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, placebo controlled, multicenter study. Patients are&#xD;
      randomized to receive either oral 4-aminosalicylic acid (4-ASA) or placebo twice a day for 12&#xD;
      weeks. After 12 weeks patients who improved with 4-ASA and those who received placebo are&#xD;
      given the option of receiving 4-ASA for an additional year.&#xD;
&#xD;
      Patients who were randomized to receive 4-ASA and continue treatment after 12 weeks are&#xD;
      followed every 3 months for 1 year. Patients who were randomized to receive placebo and begin&#xD;
      4-ASA therapy after 12 weeks are followed monthly for 3 months, then every 3 months for 1&#xD;
      year.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1995</start_date>
  <completion_date>March 1998</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>80</enrollment>
  <condition>Crohn's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>-aminosalicylic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Active small bowel Crohn's disease established by clinical evaluation and prior&#xD;
             radiologic study, endoscopy, surgical findings and/or histopathology&#xD;
&#xD;
          -  Crohn's Disease Activity Index (CDAI) must be between 150 and 450&#xD;
&#xD;
          -  No ulcerative or infectious colitis or severe perianal disease&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Biologic therapy: Not specified&#xD;
&#xD;
          -  Chemotherapy: Stable dose of no greater than 20 mg per day of prednisone allowed&#xD;
&#xD;
          -  Endocrine therapy: No immunosuppressive drugs within the past 3 months No concurrent&#xD;
             immunosuppressive drugs&#xD;
&#xD;
          -  Radiotherapy: Not specified&#xD;
&#xD;
          -  Surgery: No impending surgery No prior ileostomy or colostomy&#xD;
&#xD;
          -  Other: No 5-aminosalicylates within the past 2 weeks No concurrent 5-aminosalicylates&#xD;
             No concurrent metronidazol or ciprofloxacin&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: 18 to 80&#xD;
&#xD;
          -  Performance status: Ambulatory&#xD;
&#xD;
          -  Hematopoietic: Not specified&#xD;
&#xD;
          -  Hepatic: No hepatic disease&#xD;
&#xD;
          -  Renal: No renal disease&#xD;
&#xD;
          -  Other: Not pregnant (negative pregnancy test required) Fertile patients must use&#xD;
             effective contraception No documented salicylate allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A. Vecchio</last_name>
    <role>Study Chair</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <verification_date>January 2000</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Crohn's disease</keyword>
  <keyword>gastrointestinal disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminosalicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

